- Home
- TYRA vs GSL Comparison
TYRA vs GSL Comparison
Compare TYRA & GSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- GSL
- Stock Information
- Founded
- TYRA 2018
- GSL 2007
- Country
- TYRA United States
- GSL Greece
- Employees
- TYRA N/A
- GSL N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- GSL Marine Transportation
- Sector
- TYRA Health Care
- GSL Consumer Discretionary
- Exchange
- TYRA Nasdaq
- GSL Nasdaq
- Market Cap
- TYRA 812.7M
- GSL 877.6M
- IPO Year
- TYRA 2021
- GSL 2006
- Fundamental
- Price
- TYRA $15.36
- GSL $22.84
- Analyst Decision
- TYRA Strong Buy
- GSL Strong Buy
- Analyst Count
- TYRA 5
- GSL 1
- Target Price
- TYRA $31.00
- GSL $29.00
- AVG Volume (30 Days)
- TYRA 599.6K
- GSL 398.4K
- Earning Date
- TYRA 11-07-2024
- GSL 11-11-2024
- Dividend Yield
- TYRA N/A
- GSL 6.91%
- EPS Growth
- TYRA N/A
- GSL 7.30
- EPS
- TYRA N/A
- GSL 8.96
- Revenue
- TYRA N/A
- GSL $701,476,000.00
- Revenue This Year
- TYRA N/A
- GSL $7.05
- Revenue Next Year
- TYRA N/A
- GSL N/A
- P/E Ratio
- TYRA N/A
- GSL $2.60
- Revenue Growth
- TYRA N/A
- GSL 8.60
- 52 Week Low
- TYRA $10.60
- GSL $17.69
- 52 Week High
- TYRA $29.60
- GSL $30.32
- Technical
- Relative Strength Index (RSI)
- TYRA 34.38
- GSL 36.58
- Support Level
- TYRA $15.04
- GSL $23.40
- Resistance Level
- TYRA $16.51
- GSL $24.10
- Average True Range (ATR)
- TYRA 0.94
- GSL 0.70
- MACD
- TYRA 0.04
- GSL -0.07
- Stochastic Oscillator
- TYRA 11.68
- GSL 4.85
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
About GSL Global Ship Lease Inc New
Global Ship Lease Inc operates in the container shipping industry. The company owns and charters out containerships under long-term, fixed-rate charters to container liner companies. The majority of the company's revenues are derived from charters to MAERSK. Its fleet consisted of more than 60 containerships.